Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a clinical and C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers

[1]  J. Powers,et al.  Procalcitonin-Guided Antibiotic Discontinuation and Mortality in Critically Ill Adults: A Systematic Review and Meta-analysis. , 2019, Chest.

[2]  C. Luna,et al.  Do we need biomarkers for the follow-up and shortening of antibiotic treatment duration? , 2018, Current opinion in critical care.

[3]  M. Nijsten,et al.  Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials , 2018, Critical Care.

[4]  E. Mylonakis,et al.  Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults , 2018, Antimicrobial Agents and Chemotherapy.

[5]  A. Walker,et al.  Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care , 2018, PloS one.

[6]  A. Teixeira,et al.  Factors Associated With Short and Long Term Cognitive Changes in Patients With Sepsis , 2018, Scientific Reports.

[7]  P. Póvoa,et al.  Biomarker-guided antibiotic therapy-strengths and limitations. , 2017, Annals of translational medicine.

[8]  H. Goossens,et al.  Emergence of antimicrobial resistance to Pseudomonas aeruginosa in the intensive care unit: association with the duration of antibiotic exposure and mode of administration , 2017, Annals of Intensive Care.

[9]  John T. Menchaca,et al.  Ultra-Short-Course Antibiotics for Patients With Suspected Ventilator-Associated Pneumonia but Minimal and Stable Ventilator Settings , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  A. Bilbao,et al.  Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. , 2016, JAMA internal medicine.

[11]  Tom Dormans,et al.  Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. , 2016, The Lancet. Infectious diseases.

[12]  J. Vincent,et al.  Advances in antibiotic therapy in the critically ill , 2016, Critical Care.

[13]  Anand Kumar.  Systematic Bias in Meta-Analyses of Time to Antimicrobial in Sepsis Studies. , 2016, Critical care medicine.

[14]  E. P. Dellinger,et al.  Patients with Complicated Intra-Abdominal Infection Presenting with Sepsis Do Not Require Longer Duration of Antimicrobial Therapy. , 2016, Journal of the American College of Surgeons.

[15]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[16]  Keith M Olsen,et al.  A Multicenter Evaluation of Prolonged Empiric Antibiotic Therapy in Adult ICUs in the United States* , 2015, Critical care medicine.

[17]  V. Nobre,et al.  Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in Sepsis: A Randomized Trial* , 2013, Critical care medicine.

[18]  L. Leibovici,et al.  Duration of antibiotic treatment for acute pyelonephritis and septic urinary tract infection-- 7 days or less versus longer treatment: systematic review and meta-analysis of randomized controlled trials. , 2013, The Journal of antimicrobial chemotherapy.

[19]  F. Tubach,et al.  Procalcitonin to Guide Initiation and Duration of Antibiotic Treatment in Acute Respiratory Infections: An Individual Patient Data Meta-Analysis , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Fowler,et al.  Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis , 2011, Critical care.

[21]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[22]  J. Vincent,et al.  Sepsis biomarkers: a review , 2010, Critical care.

[23]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[24]  Anand Kumar,et al.  Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. , 2009, Chest.

[25]  S. Marsch,et al.  Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study , 2009, European Respiratory Journal.

[26]  A. Hill,et al.  C-reactive protein is an independent predictor of severity in community-acquired pneumonia. , 2008, The American journal of medicine.

[27]  J. Pugin,et al.  Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. , 2008, American journal of respiratory and critical care medicine.

[28]  J. Rello,et al.  C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia , 2008, Critical care medicine.

[29]  G. Webb,et al.  Modeling antibiotic resistance in hospitals: the impact of minimizing treatment duration. , 2007, Journal of theoretical biology.

[30]  M. Meisner,et al.  Decreases in procalcitonin and C-reactive protein are strong predictors of survival in ventilator-associated pneumonia , 2006, Critical care.

[31]  Peter Bauer,et al.  SAPS 3—From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission , 2005, Intensive Care Medicine.

[32]  Michel Wolff,et al.  Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.

[33]  V L Yu,et al.  Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.

[34]  J. Klein,et al.  Survival Analysis: Techniques for Censored and Truncated Data , 1997 .

[35]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[36]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[37]  W. Knaus,et al.  APACHE II: a severity of disease classification system. , 1985 .

[38]  H. Hemilä.  Citation bias in the CONSORT comments on blinding , 2010 .

[39]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[40]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.